Welcome to our dedicated page for Pressure Bio news (Ticker: PBIO), a resource for investors and traders seeking the latest updates and insights on Pressure Bio stock.
Pressure BioSciences Inc. (PBIO) is a biotechnology innovator specializing in pressure cycling technology (PCT) and UltraShear nanoemulsion platforms. This page provides investors and industry professionals with a comprehensive collection of official announcements, financial disclosures, and scientific developments related to the company's patented methods for enhancing bio-molecular interactions.
Access timely updates on PBIO's advancements in pharmaceutical formulation, nutraceutical delivery systems, and strategic partnerships. Key content includes earnings reports, technology licensing agreements, clinical application progress, and regulatory milestones. All materials are sourced directly from company filings and verified industry channels.
Regularly refreshed content ensures stakeholders maintain current awareness of PBIO's work in creating stable nanoemulsions for improved drug bioavailability. Bookmark this page for efficient tracking of the company's progress in pressure-based biomolecule manipulation techniques and their commercial applications.
Pressure BioSciences, Inc. (PBIO) has partnered with North Star Holdings (NSH) for the development and distribution of a novel, water-soluble nano-CBD topical spray. This collaboration is projected to generate approximately $2 million in revenue for PBIO in 2023, with NSH estimating separate revenues of $1.5 million from the spray and an additional $4.5 million from other products using PBIO’s patented Ultra Shear Technology. PBIO anticipates significant growth opportunities in various sectors including nutraceuticals and pharmaceuticals.
Pressure BioSciences (OTCQB: PBIO) announced its participation in the Emerging Growth Investor Conference on July 6, 2022. PBI's President, Richard T. Schumacher, will discuss the launch of their first UST-processed commercial product: a nanoemulsified CBD aerosol spray for oral use. This partnership with Safer Medical of Montana targets over $3 million in first-year sales, with PBI expecting to realize over $1 million from this project. The unique formulation is designed to be long-term stable and highly water-soluble, marking a significant advancement in CBD delivery.
Pressure BioSciences, Inc. (OTCQB:PBIO) announced its participation in the June 30th webinar titled Revolutionizing the Development of Plant-Based Food Products, hosted by FORCE Family Office. The event will showcase PBIO's innovative Ultra Shear Technology (UST), which converts oils and water into stable nanoemulsions, enhancing ingredient bioavailability. With the plant-based beverage market projected to reach $41B by 2027, PBIO aims to leverage UST for formulating new beverages. The webinar is scheduled for Noon ET on June 30, 2022.
Pressure BioSciences, Inc. (OTCQB: PBIO) has signed an exclusive distribution agreement with Safer Medical of Montana (SMM) for a new water-soluble CBD oral aerosol product. The partnership targets $3 million in sales within the first year, with PBIO expecting to generate over $1 million from this initiative. This marks the launch of the first product utilizing PBIO's patented Ultra Shear Technology (UST). The CBD oral spray is set for market release in Q3 2022, aiming to reach U.S. veterans and other customers through established distribution channels.
Pressure BioSciences (PBIO) announced a pivotal study from The Ohio State University showcasing the effectiveness of its patented Ultra Shear Technology™ (UST) for creating stable plant protein-based beverages. Published in Food Hydrocolloids, the study indicates UST can produce milk-pea protein blends with microscopic particle sizes, surpassing existing processing methods. This innovation targets the growing market for plant-based drinks, projected to reach $41B by 2027. PBI anticipates increased interest in UST from food and beverage companies, enhancing product quality and sustainability.
Pressure BioSciences, Inc. (OTCQB: PBIO) announced a new TechTalks video interview featuring CEO Richard T. Schumacher, focusing on the company's Early Access Program for its Ultra Shear Technology™ (UST™). This platform aims to transform oil-based active ingredients into water-soluble, highly bioavailable nanoemulsions. PBI specializes in pressure-based solutions in various industries, including biotechnology and food. The interview is available on Emerging Technology Insider's website.
Pressure BioSciences (PBIO) has launched its Early Access Program for the UST platform, with negotiations underway with four potential customers in the nutraceutical and cosmetics sectors. In Q1 2022, PBIO reported total revenue of $480,000, a 14% decrease from Q1 2021. Instrument sales fell by 19%, while consumable sales dropped by 61%. However, BaroFold/UST services increased by 59%. The operating loss slightly rose to $1,086,000, but the net loss per share improved to $(0.48). The company aims for profitability by late 2023 and plans an uplist to a major US exchange.
Pressure BioSciences (OTCQB:PBIO) has signed a multi-year development and manufacturing agreement with Safer Medical of Montana (SMM) to produce a CBD topical spray for pain relief. The partnership focuses on using PBI's Ultra Shear Technology (UST) for formulating and commercializing their product, with the first batch expected by May 31, 2022. Sales are anticipated to start in Q3 2022, targeting over 40,000 units in 2022. The agreement signals strong market demand for UST-produced nanoemulsions and highlights PBI's progress towards profitability by late 2023.
Pressure BioSciences (OTCQB: PBIO) will present at the Planet MicroCap Showcase 2022 on May 4, 2022, at 11:30 AM PDT, held at Bally's Hotel and Casino, Las Vegas. CEO Richard T. Schumacher will discuss recent advancements in nanoemulsification of CBD and other cannabinoids, along with the upcoming commercialization of their Ultra Shear Technology™ for various industries including biopharma and food/beverage. Interested parties can attend in person or via webcast.
Pressure BioSciences, Inc. (OTCQB:PBIO) has announced an Early Access Program starting July 1, 2022, for its Ultra Shear Technology (UST) platform, targeting the production of stable nanoemulsions for various industries. Due to strong demand, the company is expediting its commercialization timeline, expected to secure initial contracts in Q2 2022. UST aims to transform oil-based ingredients into transparent nanoemulsions that enhance bioavailability and stability. PBI anticipates operational tolling centers by Q4 2022, focusing on nutraceuticals, cosmetics, and agrochemicals.
FAQ
What is the current stock price of Pressure Bio (PBIO)?
What is the market cap of Pressure Bio (PBIO)?
